Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Thirty patients with progressive metastatic renal cell carcinoma were treated. Eleven patients received 2 or more prior systemic therapies; 2 had a complete response, 7 had a partial response, and 11 had stable disease. The complete responders are off therapy and remain without disease recurrence. The median duration of response was 3.8 months (range 1 - 48+ months). Therapy was well tolerated; predominant toxicities were fatigue, paraesthesias and hand/foot syndrome. The data suggest that the combination of interferon-alpha, thalidomide and capecitabine has anti-tumor activity in previously treated patients with progressive metastatic renal cell carcinoma. A prospective investigation of this combination warranted.
Amato
Robert J
RJ
The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050 Houston, TX 77030, USA. ramato@tmh.tmc.edu
Mohammad
Taqi
T
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016019:Survival Analysis; D013781:Texas; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
D016898:Interferon-alpha; D003841:Deoxycytidine; D013792:Thalidomide; D000069287:Capecitabine; D005472:Fluorouracil